Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Female participants must be of non-childbearing potential: postmenopausal for at least 2 years or surgically sterile or otherwise incapable of becoming pregnant~* Female participants, except for postmenopausal women, must have a negative serum pregnancy test at screening~* Participants must agree to comply with contraceptive measures as mentioned in protocol~* Participants must be sero-suitable for respiratory syncytial virus (RSV) within 57 days prior to inoculation~* Participants must be non-smokers for at least one month prior to screening and participants must have a negative cotinine test at screening~Exclusion Criteria:~* Participants with a past history of heart arrhythmias (extrasystoli, tachycardia at rest) or of risk factors for Torsade de Pointes syndrome~* Participants with a history or evidence of abuse of alcohol, barbiturates, amphetamines, recreational or narcotic drug use within the past 3 months, which in the Investigator's opinion would compromise participant's safety and/or compliance with the study procedures~* Participants with current human immunodeficiency virus type 1 (HIV-1) or HIV-2 infection at screening~* Participants with current hepatitis A infection, or hepatitis B virus (HBV) infection, or hepatitis C virus (HCV) infection (confirmed by HCV antibody) at screening~* Participants with active acute respiratory infection at admission (Study Day -1 or -2)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Participants will receive placebo or JNJ-53718678 500 milligram (mg) or 200 mg once daily for 7 days.
- Cohort 2 (Type: EXPERIMENTAL): Participants will receive placebo or JNJ-53718678; dosing regimen in Cohort 2 will be decided based on Cohort 1 results.
- Cohort 3 (Type: EXPERIMENTAL): Participants will receive placebo or JNJ-53718678, 75 mg once daily for 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).